Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Neuronetics ( (STIM) ) just unveiled an announcement.
Neuronetics, Inc. announced the successful acquisition of Greenbrook TMS Inc., consolidating their position in the mental health industry. This transaction will enhance their operational capabilities by integrating Neuronetics’ technology with Greenbrook’s treatment network, aiming to expand access to mental health treatments and achieve cost synergies. Greenbrook’s shares will be removed from the OTCQB Market, and the combined entity will continue as Neuronetics, trading under the NASDAQ ticker STIM.
More about Neuronetics
Neuronetics, Inc. is a global leader in neuroscience, focusing on mental health treatments. They offer the NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for neurohealth conditions like Major Depressive Disorder (MDD), and Spravato® esketamine nasal spray for treatment-resistant depression. Neuronetics operates treatment centers across the U.S., providing innovative solutions for mental health challenges.
YTD Price Performance: -60.34%
Average Trading Volume: 463,354
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $34.9M
See more data about STIM stock on TipRanks’ Stock Analysis page.
